Welcome to our dedicated page for RCM TECHNOLOGIES SEC filings (Ticker: RCMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RCM Technologies, Inc. filings document the reporting obligations of a Nevada-incorporated operating company with common stock registered on Nasdaq under the symbol RCMT. Its Form 8-K reports cover financial results, material agreements, revolving credit and loan amendments, direct financial obligations, changes in certifying accountants, and related internal control disclosures.
The company’s proxy materials address board matters, executive compensation, equity award information, and pay-versus-performance disclosure. Periodic and notice filings provide formal records around annual reporting, late-filing notifications, consolidated financial statements, risk and control matters, and the governance framework supporting RCM Technologies’ health care, engineering, information technology, life sciences, data, and solutions services.
RCM Technologies Executive Chairman & President Bradley Vizi reported a mix of stock sales and awards in company shares. On April 7–8, he sold 13,666 and 8,237 shares of common stock in open‑market transactions at weighted average prices around $27.55 and $27.52, executed under a nondiscretionary Rule 10b5‑1 trading plan.
He also received 104,266 shares as employment compensation upon vesting of previously granted performance stock units, while 41,029 shares were surrendered to cover related tax obligations through a net share settlement. After these transactions, Vizi directly holds 1,552,477 shares of RCM Technologies common stock, indicating the sales represent a small portion of his overall stake.
RCM Technologies, Inc. submitted a Form 144 notifying proposed sale of Common Stock tied to restricted‑share vesting. The notice lists 96,933 shares dated 01/15/2021, 125,000 shares dated 01/03/2023, and 50,000 shares dated 01/16/2023.
The filing identifies the securities as Common Stock, par value $0.05 and references NASDAQ with a filing date line showing 04/07/2026.
RCM Technologies, Inc. files its annual report, reporting revenue of $319.4 million for the year ended January 3, 2026, up from $278.4 million a year earlier. Specialty Health Care generated 51.4% of revenue, Engineering 37.7%, and Life Sciences, Data and Solutions 10.9%.
The company highlights growing demand tied to telemedicine, behavioral health, cleaner energy infrastructure, and hybrid IT solutions. Two customers accounted for 20.8% and 13.6% of consolidated revenue, and about 9.1% of revenue came from outside the United States.
RCM remained in compliance with its revolving credit covenants, with $24.7 million borrowed and $27.1 million available, and continued a $50 million share repurchase program, buying 114,942 shares in late 2025 at an average price of $19.48.
RCM Technologies, Inc. reported strong growth for the fourteen weeks ended January 3, 2026, with revenue of $86.5 million, up 12.4% from $76.9 million in the prior-year quarter. Gross profit rose to $24.3 million, and GAAP net income more than doubled to $6.1 million, or $0.80 per diluted share.
For the fifty-three-week fiscal year, revenue increased 14.7% to $319.4 million, while gross profit reached $87.9 million. GAAP net income grew to $16.3 million, or $2.14 per diluted share. Adjusted EBITDA improved to $30.7 million, and adjusted diluted EPS climbed to $2.50, reflecting broad-based operational strength.
RCM Technologies, Inc. notifies the SEC that it will not timely file its Annual Report on Form 10-K for the fiscal year ended January 3, 2026 because additional time is needed to finalize consolidated financial statements. The company expects to file within the fifteen calendar day extension provided by Rule 12b-25.
RCM Technologies, Inc. amended its senior credit facility with Citizens Bank to temporarily expand borrowing capacity. Under Amendment No. 1, the total revolving commitment rises from $65,000,000 to $75,000,000 from February 20, 2026 through August 31, 2026, including availability for trade and standby letters of credit.
From September 1, 2026 through the loan’s maturity, the commitment reverts to $65,000,000, and any outstanding revolving loans above that level become immediately due and payable in full on that date. The amendment otherwise leaves the existing loan terms in place and reaffirms the lender’s first-priority security interest in the borrowers’ collateral.
Conditions to effectiveness include execution of the amendment, delivery of a Thirteenth Amended and Restated Revolving Credit Note reflecting the new commitment, updated corporate certificates and schedules, and payment of a $15,000 amendment fee. The borrowers also grant a broad release of claims in favor of Citizens Bank and agree to reimburse costs and expenses related to the amendment.
RCM Technologies filed its definitive proxy for the 2025 Annual Meeting, to be held virtually on December 18, 2025 at 4:00 p.m. ET. Stockholders of record as of October 22, 2025, may vote; there were 7,410,510 shares of common stock outstanding on the record date.
Key items include the election of four directors and approval of the 2025 Omnibus Equity Compensation Plan authorizing up to 1,000,000 shares. The plan features a general one‑year minimum vesting schedule (with limited exceptions), a $100,000 annual equity limit for non‑employee directors, and eligibility for employees, directors, and consultants. The filing outlines standard voting/quorum procedures and virtual attendance steps. Reported beneficial owners include Ben Andrews at 535,048 shares (7.2%) and Renaissance Technologies LLC at 485,473 shares (6.6%). The Summary Compensation Table shows 2024 total compensation of $7,731,221 for Executive Chairman & President Bradley S. Vizi, with details on PSU/RSU grants and outcomes.
RCM Technologies (RCMT) reported Q3 2025 results with revenue of $70.3 million and diluted EPS of $0.30. Operating income was $3.9 million. For the first thirty‑nine weeks, revenue reached $232.9 million and diluted EPS was $1.34, as operating income rose to $17.1 million.
Growth was led by Engineering (Q3 revenue $31.4 million) and Specialty Health Care ($30.0 million), while Life Sciences, Data & Solutions posted $8.9 million. Gross profit for the quarter was $19.4 million on cost of services of $50.9 million. Two customers represented 19.6% and 13.2% of year‑to‑date revenue, both within Specialty Health Care.
Cash was $1.3 million, borrowings under the line of credit were $31.5 million, and letters of credit outstanding were $13.1 million. The revolving credit facility was amended to $65.0 million with maturity on December 3, 2029. The company repurchased 301,640 shares at an average price of $16.89 during the first thirty‑nine weeks, with $37.1 million remaining under the authorization. Common shares outstanding were 7,410,510 as of November 5, 2025.
RCM Technologies, Inc. filed a current report to note that it has issued a press release covering its financial results for the thirteen and thirty-nine weeks ended September 27, 2025. The press release is furnished as Exhibit 99 to the report and contains the detailed figures and discussion of operating performance for those periods.
The company specifies that the information in the results section, including the exhibit, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal and liability purposes. The report also confirms there were no acquired-business financial statements, no pro forma financial information, and no shell company transactions included.
Bradley S. Vizi, Executive Chairman & President of RCM Technologies, Inc. (RCMT), reported three sales of the issuer's common stock on 09/22/2025–09/24/2025 under a nondiscretionary Rule 10b5-1 plan established 12/07/2023. Total reported disposition was 1,258 shares at a weighted average price of approximately $27.50 per share. After these transactions the reporting person beneficially owned 1,511,333 shares directly. The filing discloses the sales were pre-arranged and the filer will provide specific per-price breakdowns on request.